Loading company…
SONOMIND is developing non-invasive ultrasound treatment for depression.
Founded in 2024 and based in Paris, SONOMIND is developing ultrasound neuromodulation for depression, including treatment-resistant cases. Its approach uses deep transcranial ultrasound stimulation. In May 2026, the company raised EUR 20 million in Series A funding co-led by Critical Path Ventures and Bpifrance Investissement to advance development and clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in